IE
OMED

Israel Englander’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Israel Englander’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-400,700
Closed -$3.69M – 4217
2017
Q1 		$3.69M Buy
+400,700
New +$3.52M 0.01% 1633

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Israel Englander's OMED Position: Q4 2018 in Review

Israel Englander sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 49,557 shares — an estimated $105K sold.

Israel Englander first reported a position in OMED in Q3 2013 and held it in 15 quarters. The position peaked at $7.45M in Q3 2016. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Israel Englander reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Israel Englander sold 49,557 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $105K.
  • Israel Englander first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 15 quarters.
  • Israel Englander's OncoMed Pharmaceuticals, Inc. position peaked at $7.45M in Q3 2016.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Millennium Management's 13F filing for Q4 2018, filed 14 Feb 2019.